NorthStar Medical Radioisotopes LLC will unveil the commercial model of its RadioGenix isotope separation system during three events on March 27 and March 28 at The Keating Hotel in San Diego. The events will be the first public demonstrations of system enhancements directly inspired by recommendations made by nuclear pharmacists during similar events last year.

Sterne Agee, ACC, Medtronic, Edwards, St. Jude, TAVR, heart failure

The American College of Cardiology (ACC) hosted its 64th Annual Scientific Session & Expo over the weekend in San Diego, California. Key data from multiple transcatheter aortic valve replacement (TAVR) clinical trials were presented and we believe there was truly no loser between Edwards and Medtronic based on the positive data presented. In addition, St. Jude Medical announced retrospective analysis on CHAMPION data showing significant reduction in mortality rates and heart failure (HF) hospitalizations for heart failure patients with reduced ejection fraction.
CoreValve, high risk study, TAVR, Medtronic, ACC
CoreValve, high risk study, TAVR, Medtronic, ACC

Medtronic plc unveiled new two-year data from the CoreValve U.S. Pivotal High Risk Study, which demonstrated superior two-year survival benefits from transcatheter aortic valve replacement (TAVR) with the CoreValve System compared to surgical aortic valve replacement (SAVR).
Edwards, Sapien, PARTNER trial, five-year outcomes, ACC

Five-year data suggest that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart surgery, though valve leakage was more common with the first-generation valve evaluated in this study than with surgery, according to research from PARTNER I presented at the American College of Cardiology’s (ACC) 2015 Annual Scientific Session.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now